Difference between revisions of "Nilotinib (Tasigna)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
m |
||
| Line 22: | Line 22: | ||
==Also known as== | ==Also known as== | ||
| − | AMN107 | + | *'''Code name:''' AMN107 |
| + | *'''Brand name:''' Tasigna | ||
==References== | ==References== | ||
| Line 28: | Line 29: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
[[Category:Bcr-Abl inhibitors]] | [[Category:Bcr-Abl inhibitors]] | ||
| + | [[Category:CSF1R inhibitors]] | ||
| + | [[Category:DDR inhibitors]] | ||
| + | [[Category:KIT inhibitors]] | ||
[[Category:PDGFR inhibitors]] | [[Category:PDGFR inhibitors]] | ||
Revision as of 21:10, 24 August 2017
General information
Class/mechanism: Tyrosine kinase inhibitor of Bcr-Abl, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome abnormality in CML. Nilotinib binds to the inactive conformation of the Abl kinase domain and stabilizes it.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute lymphocytic leukemia
- Chronic myelogenous leukemia
- Hypereosinophilic syndrome
- Systemic mastocytosis
Patient drug information
- Nilotinib (Tasigna) package insert[1]
- Nilotinib (Tasigna) patient drug information (Chemocare)[4]
- Nilotinib (Tasigna) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 10/29/2007: Granted FDA accelerated approval for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior therapy that included Imatinib (Gleevec).
- 6/17/2010: New indication for the treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Also known as
- Code name: AMN107
- Brand name: Tasigna
References
- Drug index
- Oral medications
- Kinase inhibitors
- Bcr-Abl inhibitors
- CSF1R inhibitors
- DDR inhibitors
- KIT inhibitors
- PDGFR inhibitors
- Acute lymphocytic leukemia medications
- Chronic myelogenous leukemia medications
- Hypereosinophilic syndrome medications
- Systemic mastocytosis medications
- Drugs FDA approved in 2007
- WHO Essential Cancer Medicine